Skip to main content
Premium Trial:

Request an Annual Quote

EMD to Use Starpharma's Dendrimers for DNA and siRNA Transfection Research

NEW YORK (GenomeWeb News) — EMD Biosciences will use Starpharma’s dendrimers for DNA and siRNA transfection research, EMD said today.
Under the terms of the license and supply agreement, Starpharma’s US subsidiary Dendritic Nanotechnologies will supply EMD with the Priostar technology in exchange for royalties and milestones.
DNT will retain the full rights to use Priostarall for in vivo transfection research.
Lisa Johnson, EMD’s vice president of corporate development, said the company plans to develop new transfect ion reagents, which EMD will market under the Novagen brand. 
Johnson said the company sees the transfection reagent market as “rapidly growing,” and said EMD plans to make this technology “a foundation for future product platforms."
Financial terms of the agreement were not released.

The Scan

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.

Team Presents Cattle Genotype-Tissue Expression Atlas

Using RNA sequences representing thousands of cattle samples, researchers looked at relationships between cattle genotype and tissue expression in Nature Genetics.

Researchers Map Recombination in Khoe-San Population

With whole-genome sequences for dozens of individuals from the Nama population, researchers saw in Genome Biology fine-scale recombination patterns that clustered outside of other populations.

Myotonic Dystrophy Repeat Detected in Family Genome Sequencing Analysis

While sequencing individuals from a multi-generation family, researchers identified a myotonic dystrophy type 2-related short tandem repeat in the European Journal of Human Genetics.